Amneal Pharmaceuticals (NASDAQ:AMRX) Releases FY 2025 Earnings Guidance

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share guidance of 0.650-0.700 for the period, compared to the consensus earnings per share estimate of 0.710. The company issued revenue guidance of $3.0 billion-$3.1 billion, compared to the consensus revenue estimate of $2.9 billion.

Analysts Set New Price Targets

Several equities research analysts have commented on AMRX shares. StockNews.com lowered Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Thursday, December 19th. Barclays increased their target price on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a research report on Monday. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their price target for the company from $9.00 to $12.00 in a research report on Monday, February 24th. Finally, Piper Sandler increased their price objective on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an "overweight" rating in a research report on Monday, November 11th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Amneal Pharmaceuticals presently has an average rating of "Buy" and an average target price of $10.80.

Remove Ads

Amneal Pharmaceuticals Price Performance

Amneal Pharmaceuticals stock traded up $0.08 during midday trading on Tuesday, hitting $8.84. 1,788,222 shares of the company were exchanged, compared to its average volume of 1,363,430. The company has a market cap of $2.74 billion, a PE ratio of -13.00 and a beta of 1.10. Amneal Pharmaceuticals has a fifty-two week low of $5.18 and a fifty-two week high of $9.48. The company's fifty day moving average price is $8.12 and its 200-day moving average price is $8.33.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its earnings results on Friday, February 28th. The company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.15 by ($0.03). The firm had revenue of $730.52 million for the quarter, compared to analyst estimates of $708.21 million. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. During the same period in the previous year, the firm posted $0.14 earnings per share. On average, analysts expect that Amneal Pharmaceuticals will post 0.53 EPS for the current fiscal year.

Insider Buying and Selling at Amneal Pharmaceuticals

In other news, Director Gautam Patel sold 62,590 shares of the stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $8.01, for a total transaction of $501,345.90. Following the completion of the transaction, the director now directly owns 1,968,886 shares in the company, valued at approximately $15,770,776.86. This represents a 3.08 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 160,000 shares of company stock valued at $1,292,000 in the last ninety days. Insiders own 26.56% of the company's stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.